Author + information
- Ibadete Bytycia,b,
- Gani Bajraktaria,b,
- Deepak L. Bhatta,b,
- Charity J. Morgana,b,
- Ali Ahmeda,b,
- Wilbert S. Aronowa,b,
- Maciej Banacha,b,
- on behalf of the Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group
Background: Hydrophilic statins may be more beneficial than lipophilic statins in patients with acute ischemia undergoing percutaneous coronary intervention (PCI). In the current meta-analysis we examined the effect of lipophilic in comparison with hydrophilic statins in patients with acute coronary syndrome (ACS) and undergoing PCI.
Methods: We systematically searched selected electronic databases up to July 2016 in order to identify randomized controlled trials (RCTs) which compared clinical outcomes of hydrophilic vs. lipophilic statins in ACS patients. Primary outcomes were major adverse cardiac events (MACE), myocardial infarction (MI), cardiac revascularization, stroke, cardiovascular (CV) hospitalization, cardiovascular (CV) and all-cause of mortality.
Results: A total of 8708 patients from 8 RCTs had been randomized to receive lipophilic (n=4277) or hydrophilic statins (n=4431), with mean follow-up 12.4 months, and were included to the meta-analysis. In comparison to hydrophilic statins, the lipophilic statins showed comparable risk reduction of MACE (relative risk [RR]=1.05, 95% CI, 0.88 to 1.25, p=0.591; Figure). Similar effects were observed on MI and CV death (Figure) and other outcomes.
Conclusions: We found no evidence of differential effect on MACE or other outcomes between lipophilic and hydrophilic statins in patients with ACS undergoing PCI.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Advances in Lipid Management
Abstract Category: 3. Acute and Stable Ischemic Heart Disease: Therapy
Presentation Number: 1203-315
- 2017 American College of Cardiology Foundation